Î’-lactam-associated neutropenia: Difference between revisions
From IDWiki
Î’-lactam-associated neutropenia
(Created page with "{{DISPLAYTITLE:β-lactam-associated neutropenia}} == Background == * Adverse reaction to β-lactam antibiotics occurring in about 1 to 10% of prolonged courses * Higher risk with penicillin G, nafcillin, oxacillin, piperacillin-tazobactam, ceftriaxone, and ceftaroline * Risk increases with cumulative exposure * Mechanism is unclear; may be some combination of a direct toxic effect or an Hypersensitivity reaction|immune-mediated...")  |
(→â€)  |
||
Line 3: | Line 3: | ||
== Background == |
== Background == |
||
* Adverse reaction to [[Β-lactams|β-lactam antibiotics]] occurring in about |
* Adverse reaction to [[Β-lactams|β-lactam antibiotics]] occurring in about 10% of courses longer than 2 weeks |
||
* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]] |
* Higher risk with [[penicillin G]], [[nafcillin]], [[oxacillin]], [[piperacillin-tazobactam]], [[ceftriaxone]], and [[ceftaroline]] |
||
* Risk increases with cumulative exposure |
* Risk increases with cumulative exposure |
||
Line 11: | Line 11: | ||
* [[Neutropenia]] |
* [[Neutropenia]] |
||
* Usually presents after 2 to 3 weeks of parenteral antibiotics |
|||
* Rash in 25-50% of cases |
|||
* May have associated [[eosinophilia]] or [[thrombocytopenia]] |
|||
* Can progress to [[agranulocytosis]] |
* Can progress to [[agranulocytosis]] |
||
== Management == |
== Management == |
||
* |
* Consider stopping the offending antibiotic if ANC falls below 1 |
||
* Other β-lactam antibiotics are probably still safe to use |
* Other β-lactam antibiotics are probably still safe to use |
||
Latest revision as of 03:20, 24 July 2022
Background
- Adverse reaction to β-lactam antibiotics occurring in about 10% of courses longer than 2 weeks
- Higher risk with penicillin G, nafcillin, oxacillin, piperacillin-tazobactam, ceftriaxone, and ceftaroline
- Risk increases with cumulative exposure
- Mechanism is unclear; may be some combination of a direct toxic effect or an immune-mediated hypersensitivity reaction
Clinical Manifestations
- Neutropenia
- Usually presents after 2 to 3 weeks of parenteral antibiotics
- Rash in 25-50% of cases
- May have associated eosinophilia or thrombocytopenia
- Can progress to agranulocytosis
Management
- Consider stopping the offending antibiotic if ANC falls below 1
- Other β-lactam antibiotics are probably still safe to use
Further Reading
- A Review of β-Lactam-Associated Neutropenia and Implications for Cross-reactivity. Ann Pharmacother. 2021;55(8):1037-1049. doi: 10.1177/1060028020975646